|
In Play®
|
||
| 16:46 | PRX Par Pharmaceutical: Strativa Pharmaceuticals provides an update on Zuplenz (Ondansetron) oral soluble film; the FDA has been unable to perform an inspection; FDA cannot approve the application at this time (25.99 +1.20) | |
| Co announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the new drug application (NDA) for Zuplenz (ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery. Due to an agency-wide restriction on foreign travel in India, the FDA has been unable to perform an inspection of the clinical and analytical sites for a bioequivalence study, and therefore, cannot approve the application at this time. The FDA advised that they will schedule and perform an inspection of these sites as soon as possible. Strativa will continue to work with the FDA on completing these site inspections and finalization of product labeling. No | ||
| 16:41 | TBNK Territorial Bancorp reports Q4 EPS of $0.27 vs. $0.25 First Call consensus (18.03 +0.31) | |
| Total delinquent loans ninety days or more past due and not accruing was $277,000 (representing five loans) at December 31, 2009, compared to $0 at December 31, 2008. Despite the increase in non-performing assets, asset quality remained strong with the ratio of non-performing assets to total assets being 0.11% at December 31, 2009, compared to 0.02% at December 31, 2008. The allowance for loan losses was $1.7 mln at December 31, 2009 compared to $899,000 at December 31, 2008. The ratio of the allowance for loan losses to total loans was 0.28% at December 31, 2009 compared to 0.14% at December 31, 2008. | ||
| 16:37 | FIT Health Fitness: Trustmark and FIT announce early termination of Hart-Scott-Rodino Waiting Period (8.77 -0.01) | |
| 16:37 | VRUS Pharmasset files $150 mixed securities shelf offering in an S-3 filing (21.90 +0.75) | |
| 16:30 | DGX Quest Diagnostics reaffirms 2010 EPS and revs in-line with consensus (55.60 +0.17) | |
| Co announced that it is scheduled to speak at the UBS 2010 Global Healthcare Services Conference in New York City. The presentation is scheduled for Wednesday, February 10, 2010 at 9:00 a.m. Eastern Time. During the conference, the co will reaffirm its 2010 guidance for revenue growth of 3-4%, which equates to ~$7.68-7.75 bln vs. $7.71 bln. Co also said operating income is expected to approach 19% of revenues, and diluted EPS of between $4.10-4.30 vs. $4.22 First Call consensus. | ||
| 16:17 | AMAG AMAG Pharma provides Feraheme safety update (37.77 -0.35) -Update- | |
| Co provided a safety update on Feraheme Injection for intravenous use. Since the commercial launch of Feraheme in July 2009, serious adverse events have been reported at a rate consistent with that contained in the U.S. package insert. Of the estimated 35,000 patient exposures to date, 40 serious adverse events have been reported, an approximate rate of 0.1%. No mortality signal has been observed. A single reported death occurred in a patient two days post-Feraheme treatment, which the Company does not believe was the result of Feraheme... Feraheme is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme is contraindicated in patients with evidence of iron overload, known hypersensitivity to Feraheme or any of its components, and patients with anemia not caused by iron deficiency. In clinical studies, hypotension was reported in 1.9% of subjects receiving Feraheme, including three patients with serious hypotensive reactions. Serious hypersensitivity reactions were reported in 0.2% of patients. Patients should be observed for signs and symptoms of hypersensitivity for at least 30 minutes following Feraheme injection and the drug should only be administered when treatment for hypersensitivity reactions is readily available. Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy. As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging but will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging. In clinical trials, the most commonly occurring adverse reactions in Feraheme treated patients versus oral iron treated patients were diarrhea, nausea, dizziness, hypotension, constipation and peripheral edema. | ||
| 16:05 | HDNG Hardinge confirmed that it received an unsolicited proposal from Industrias Romi S.A. of Brazil to acquire all of its outstanding shares for $8.00 per share (8.07 ) | |
|
||
| 15:45 | GDX Sector ETF strength & weakness approaching today's closing bell -Technical- | |
| Actively Traded Leading Sector ETF Plays: Gold miners- GDX +4.5%, SPDRS metals/mining- XME +2.75%, Semis- SMH +2.25%, IGW +2%, nat gas- UNG +1.75%, VIX volatility index- VXX +1.5%, iShares REITS & real estate- ICF +1.5%, IYR +1.5%, Basic materials- XLB +1.25%, IYM +1.25%, iShares US broker/dealers- IAI +1.25%, SPDRS tech.- XLK +.75%, Regional banks- KRE +.75%, Commercial banks- KBE +.5%, Financials- XLF +.5%, IYF +.5%, NDX 100- QQQQ +.5%, Steel- SLX +.5%, US Dollar index- UUP +.5% Actively Traded Lagging Sector ETF Plays: RBOB gas- UGA -2.25%, Heating oil- UHN -2.25%, Base metals- DBB -2%, Global shippers- SEA -2%, Crude/WTI oil- USO -1.75%, OIL -2%, Commods- GSG -1.75%, DBC -1.25%, India- INP -1.75%, iShares S Korea- EWY -1.25%, Emerging mkts- EEM -1.25%, China 25- FXI -1.25%, Silver- SLV -1.25%, SPDRS homebuilders- XHB -1% |
||
| 15:41 | Earnings Preview for the week of Feb 8th-12th: | |
| Of the hundreds of companies reporting earnings the week of Feb 8th-12th some of the bigger names include: Monday: BWP, CVS, ERTS, ESLR, FWRD, LNC, and TWTC... Tuesday: BIIB, BJS, KO, CTSH, CVH, TAP, NYX, WMG, NTGR, and DIS... Wednesday: MT, CCE, DF, DISCA, ELN, ICE, LVLT, S, WYN, ALL, BSX, PL, PRU, and SWIR... Thursday: ALU, EXPE, FLIR, JASO, MAR, PEP, PM, STRA, VIA.B, ACL, AB, BJRI, NILE, BWLD, CEPH, CAKE, CMG, CSTR, MFE, and PNRA... Friday: ALE, HCP, PAS, and UPL. | ||
| 15:32 | Conferences and Shareholder/Analyst Meetings of Interest | |
|
Monday: - WAG, HUM, UAM, WLP at UBS Global Healthcare Services Conference - $24 bln 3-month and $27 bln 6-month Treasury Bills Auctions - LINC, FFIV, PENN, RAX at Deutsche Bank Securities Small and Mid Cap Conference Tuesday: - ODSY, MHS, AET, SUNH at UBS Global Healthcare Services Conference - RHT, SAP, ADBE, ENTR at Thomas Weisel Technology & Telecom Conference - $40 bln 3-yr Treasury Notes Auction Wednesday: - AMTD, BAC, COF, WFC at Credit Suisse Financial Services Conference - AMSC, FLO, FMC, POWI at Deutsche Bank Securities Small and Mid Cap Conference - Fed's Tarullo Thursday: - ZION Analyst Meeting - AMP, LNC, MET, NYX at Credit Suisse Financial Services Conference - $16 bln 30-yr Treasury Bond Auction Friday: - AXAS at NAPE Expo 2010 |
||
| 15:10 | TALKX Floor Talk: Late market pop as late-day buying ignites an aggressive round of short-covering; seeing highest volume of the day on this bar -Technical- | |
| 15:08 | SPY S&P -3.8 embarks on best rebound of the day, edges above intraday resistance at 1054/1055 -Update- -Technical- | |
| 14:57 | BRCM NASDAQ 100 (NDX) leaders & laggards moving into today's final hour of trading -Technical- | |
| NDX 100 Best % Performers: BRCM +5.5%, AMAT +2%, HANS +1.5%, ALTR +1.5%, GENZ +1.25%, CSCO +1.25%, LRCX +1.25%, INTC +1.25%, ROST +1%, ORCL +1%, RIMM +.75%, LLTC +.5% NDX 100 Worst % Performers: FWLT -8%, LBTYA -4%, VRTX -4%, ILMN -3.75%, LOGI -3%, NWSA -3%, HOLX -3%, NIHD -3%, WCRX -2.75%, CHRW -2.75%, CELG -2.75%, NRG -2.75% NASDAQ TRIN @ +1.15 NASDAQ A/D @ -855 |
||
| 14:53 | CSCO Dow (INDU) leaders & laggards moving into today's final hour of trading -Technical- | |
| INDU Best % Performers: CSCO +1%, INTC +1% INDU Worst % Performers: GE -4.25%, BA -3%, MRK -2.25%, MMM -2%, DIS -1.75%, MCS -1.75%, JPM -1.75%, CVX -1.75% NYSE TRIN @ +1.3 NYSE A/D @ -1780 |
||
| 14:51 | SPY S&P 500 stabilizes after minor breach of 200 day ema but below intraday line in the sand -Update- -Technical- | |
| (Click for 5 min chart). | ||
| 14:44 | GLD streetTRACKS Gold Shares ETF makes move to session highs along with the GDX ETF (104 -.37) -Update- -Technical- | |
| Some names hitting the new high tape include RGLD, NEM, GOLD, ABX, GDXJ, LIHR, GG | ||
| 14:44 | COMDX CBOT Agriculture and Ethanol and ICE Exchange Sugar Closing Prices | |
| March corn closed lower by 2.5 cent to $3.5150 per bushel, March soybeans closed lower by 0.50 cents to $9.1350 per bushel, March wheat closed lower by 2.50 cents to $4.7325 per bushel, March Ethanol closed lower by $0.025 at $1.75, March world sugar futures closed 1.47 cents lower at 26.17 cents per pound. | ||
| 14:39 | COMDX NYMEX Energy Closing Prices | |
| Crude oil ended the day lower by $1.95 to $71.19, natural gas finished higher by 10.2 cents to $5.518, heating oil shed 6.16 cents to settle at $1.8736 and RBOB gasoline closed lower by 6.53 cents to $1.8855 (all March contracts). | ||
| 14:01 | SPY Stock indices continue to weaken/Dollar Index sets new high -- Dow -156, S&P -17, Nasdaq -22 -Update- -Technical- | |
| 14:00 | PATR Patriot Transportation announces agreement to sell land (88.58 0.00) | |
| Co announced that a subsidiary of the Company, Florida Rock Properties, entered into an agreement to sell ~1,844 acres of land in Caroline County, Virginia, to the Commonwealth of Virginia, Board of Game and Inland Fisheries. The purchase price for the property is $5,200,000. Co is also donating the value of minerals and aggregates. The agreement of sale is subject to certain contingencies including satisfactory completion of the buyer's inspection period, review of the appraisal, federal government funding and additional government approvals. The contract expires if not completed before September 21, 2010. The Company's book value of the property is $222,000. If the sale closes, the Company may use the proceeds in a 1031 exchange for the purchase of real estate. | ||
| 13:58 | IWM iShares Russell 2000 and IWM join S&P 500 in test of its 200 day ema -Technical- | |
| (Click for chart). | ||
| 13:45 | SPY S&P 500 tests 200 ema for first time since the July breakout at 1046 -Update- -Technical- | |
| (Click for chart). | ||
| 13:36 | SPY S&P 500 brings slide off Jan high to 100 points -- session low 1050 -Update- -Technical- | |
| Its 200 day ema comes into play today at 1046. | ||
| 13:33 | UUP Dollar Index holds above intraday support, edging back toward session high at 80.61 -Update- -Technical- | |
| (see Dollar Index chart is 12:39 update). | ||
| 13:32 | COMDX COMEX Metals Closing Prices | |
| April gold ended off $9.50 to $1053.20, March silver shed 47 cents to close at $14.88 and March copper finished down 2.15 cents to $2.8575. | ||
| 13:31 | MCD McDonald's slides to new session low of 62.96 under midday trough, its 50 day sma comes in at 62.76 (62.96 -1.09) -Technical- | |
| 13:29 | UPS UPS flirts with its late Nov range lows near 56.50 -- session low 56.54 (5.58 -0.71) -Technical- | |
| Note that its 200 day ema comes into play at 56.11. | ||
| 13:28 | TLCR Talecris Biotherapeutics receives orphan drug designation for aerosolized alpha1-proteinase inhibitor to treat alpha1-antitrypsin deficiency (22.39 -0.88) | |
| Co announces that it was granted orphan drug designation by the FDA for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor to treat congenital alpha1-antitrypsin deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency. | ||
| 13:17 | COMDX Natural gas gives up all of its gains to trade into negative territory; now off a penny to $5.406 | |
| 13:11 | TIN Temple-Inland increases quarterly dividend by 10% to $0.11 per common share (16.21 -0.58) | |
| 13:11 | SPY S&P 500 -8.1 dips to minor new session low, Dow -70 and Nasdaq -4.7 still holding above -Update- -Technical- | |
| Relative weakness in recent trade (underperforming the S&P) Finance XLF / RKH, Housing XHB, REITs IYR, Coal KOL, Steel SLX, Ag/Chem MOO. | ||
| 13:03 | Moody's upgrades GMAC to B3 with a stable rating outlook; maintains ResCap's C rating | |
| 12:45 | VXX Sector ETF strength & weakness here @ midday trading -Technical- | |
| Actively Traded Leading Sector ETF Plays: VIX volatility- VXX +3%, Nat gas- UNG +1.25%, Semis- SMH +1%, IGW -.75%, Livestock commods- COW +.85%, US Dollar index- UUP +.75%, iShares real estate & REITS- ICF +.5%, IYR +.5%, Gold miners- GDX +.5%, SPDRS basic materials- XLB +.25%, SPDRS tech- XLK +.25% Actively Traded Lagging Sector ETF Plays: RBOB gas- UGA -4%, Heating oil- UHN -3.5%, Crude/WTI oil- USO -3.25%, OIL -3.5%, Silver- SLV -3.5%, Global shippers- SEA -3%, Commods- GSG -3%, DBC -2.25%, iShares S Korea- EWY -2.5%, iShares Brazil- EWZ -2.5%, Emerging mkts- EEM -2.5%, Solar power- TAN -2.5%, China 25- FXI -2.25%, Oil HLDRS- OIH -2% |
||
| 12:41 | BHI Baker Hughes reports Jan international rig count of 1047, up 23 from the 1024 in December and up 3 from 1044 a year ago (43.40 -1.82) | |
| 12:39 | UUP Dollar Index advance gets market's attention -Update- -Technical- | |
| The S&P had maintained a very tight inverse relationship with the Dollar Index for months as the latter dropped steeply off its March 2009 peak. The first leg up in the Dollar off the 52-wk low in Nov did not trigger pressure in the S&P as it instead drifted sideways for several weeks. The Jan slide in the Dollar Index alleviated pressure with the S&P able to reach a new 52-wk high. However, the Dollar held at its 50 day averages and has rebounded aggressively over the last several weeks with this second leg apparently eliciting more interest in the stock market (Click for chart). Intraday watching the 80.40/80.30 support area in the Dollar as it slips back off the high (80.61). A posture above would leave the door open for a run back to the high with next resistance at 80.82/80.88 (equality target and July peak). | ||
| 12:32 | SPY NYSE volume pacing ahead of yesterdays tally thus far, NASDAQ well below-- See volume charts -Technical- | |
| Three hours into today's trading session, the NYSE trading volume is pacing ahead of yesterday's above average totals which signalled very aggressive bearish distribution by mutual funds, hedge funds, & institutions. With the SPX down nearly -.50%%, we could be seeing a follow-through bearish price/volume pattern relationship. Conversely, the NASDAQ volume is noticeably below yesterday's tally thus far in the session, signalling a potential ease in the bearish selling pressure exhibited yesterday. As of 12:30ET, nearly 624m shares have changed hands on NYSE vs. yesterday's 594M, while on NASDAQ, 1.31b shares have traded vs. the 1.41B seen yesterday. NYSE 60 min volume chart NASDAQ 60 min volume chart |
||
| 11:52 | ZBB ZBB Energy announces retirement of COO and new, expanded roles for key executives (1.27 -0.03) | |
| Co announced that, Steven A. Seeker, Chief Operating Officer of the Company, announced his retirement. In connection with his retirement, the Company has entered into agreement with Mr. Seeker that employment with the Company will end effective June 30, 2010 and that prior to such retirement, Seeker will be on a paid leave of absence from the Company. Co also announced today that, Scott Scampini, ZBB's Executive Vice President and Chief Financial officer was appointed to the additional position of Executive Vice President Operations. | ||
| 11:48 | COMDX Gold and silver set fresh lows, at $1045.50 and $14.65 respectively, as the dollar index surges to fresh highs | |
| Gold is now off $17.00 to $1046.10; silver is lower by 68 cents to $14.67. | ||
| 11:44 | COMDX Crude oil now trading below the $70 level; currently down $3.45 to $69.67 | |
| Weakness in crude oil is reigning in the rally in natural gas. Nat gas has now given back almost all of its earlier gains and is trading up 4.4 cents to $5.46. | ||
| 11:44 | SPY New low Dow -92 and S&P -8, Nasdaq -8.7 hovering just above -Update- -Technical- | |
| 11:36 | COMDX Crude oil notches fresh lows at $70.69, its worst levels since Dec 16, 2009, as the dollar index trades to fresh highs; crude now off $2.22 to $70.92 | |
| 11:36 | SPY Stock indices slip back off rebound highs as Dollar Index retests highs and Financials falter -- Dow -61, S&P -5.9, Nasdaq -2.4 -Update- -Technical- | |
| 11:30 | COMDX Crude oil drops sharply to its lowest levels of the session at $71.75; now down $1.03 to $72.11 | |
| 11:23 | Rumor Round Up | |
| We ended the week with another slow rumor session. At the open renewed takeover chatter circulated on Human Genome (HGSI 26.44 +0.34), with Amgen (AMGN 57.41 -0.12) and GlaxoSmithKline (GSK 37.91 -0.57) the speculated acquirers. Potash (POT 102.07 +0.18) was also rumored to be hearing interest from BHP Billiton (BHP 68.12 -0.25). We note POT takeover chatter has been circulated in the past and the stock has not reacted to the rumor. As mentioned before, while many rumors circulate during the day, and the validity of the source of these rumors can be questionable, the speculation may increase volatility in the near term. | ||
| 11:22 | PEP PepsiCo shares slide to session lows as price probes notable technical price support here surrounding the 59.00 mark (59.16 -.48) -Technical- | |
| The late Jan. swing/tail low stands @ 59.12 & converges almost to the tick with the 200-day EMA here. Also note the mid-Dec. swing low in play just below current levels @ 58.77. PEP LoD now @ 59.09 & notably underperforming the SPX @ -.8% vs. -.25% |
||
| 11:15 | COF Capital One sets minor new session low of 34.88, hovering above yesterday's low at 34.85 (34.93 -0.01) -Technical- | |
| Note that if follow through develops, its 200 day ema and Jan/four month low come into play at 34.68/34.65. | ||
| 11:10 | GLD streetTRACKS Gold Shares stabilizes near top of Nov gap at 103.25 -- session low 103.18 (103.77 -0.60) -Technical- | |
| However, only a minor lift after flirting with the upper end of the Nov gap has been noted thus far. Secondary support is at the bottom of the gap at 102.66. It hit 104.15 on the initial rebound and drifted so watching this area (also includes 50 sma/ema 5 min chart) to see if follow through interest can develop -- GG, AEM, FCX, ABX, NEM, KGC, AU, IAG, GFI, HMY. | ||
| 10:55 | WTW Weight Watchers settles lawsuit with Jenny Craig (28.40 -0.32) | |
| Co announced it has settled its legal dispute with Jenny Craig. Under the terms of the settlement, Jenny Craig has permanently agreed to terminate its advertising campaign, which made false and misleading claims about the success of their program versus the Weight Watchers program. On January 19, 2010, Weight Watchers filed a lawsuit in the U.S. District Court for the Southern District of New York charging that Jenny Craig's advertising campaign featured false and misleading claims. The Court granted Weight Watchers' request for a temporary restraining order prohibiting Jenny Craig from broadcasting, publishing or disseminating its deceptive advertisements. | ||
| 10:35 | UNG Sector ETF strength & weakness through today's 1st hour of trading -Technical- | |
| Actively Traded Leading Sector ETF Plays: UNG +2.75%, iShares real estate & REITS- IYR +2%, ICF +2%, Semis- SMH +1.75%, IGW +1.25%, Regional banks- KRE +1%, RKH +.75%, Basic materials- XLB +.75%, IYM +.5%, iShares US broker/dealers- IAI +1%, SPDRS metals/mining- XME +.75%, Financials- XLF +.75%, IYF +.75%, Commercial banks- KBE +1%, SPDRS tech- XLK +1% Actively Traded Lagging Sector ETF Plays: Global shippers- SEA -2.25%, US airlines- FAA -2.25%, India- INP -1.75%, iShares Brazil- EWZ -1.75%, iShares S Korea- EWY -1.75%, SIlver- SLV -1.5%, Emerging mkts- EEM -1.25%, China 25- FXI -1.25%, Base metals- DBB -1%, Coal- KOL -1%, Solar power- TAN -1%, Oil HLDRS- OIH -1% |
||
| 10:29 | UUP Dollar Index and UUP stall on retest of morning highs, helps to underpin Energy/Commodity in recent action -Technical- | |
| 10:29 | LRCX NASDAQ 100 (NDX) leaders & laggards moving thorugh today's 1st hour of trading -Technical- | |
| NDX 100 Best % Performers: LRCX +1.5%, ROST +1.5%, INTC +1.25%, AAPL +1.25%, BRCM +1.25%, KLAC +1.25%, INTU +1%, ORCL +1.25% NDX 100 Worst % Performers: FWLT -5.25%, LBTAY -3.25%, ILMN -3%, LOGI -2%, VRTX -2%, RYAAY -1.75%, HOLX -1.5%, JOYG -1.25%, STX -1%, NRG -1.5%, AKAM -1% NASDAQ TRIN @ +.50 NASDAQ A/D @ -455 |
||
| 10:28 | SMH Intraday relative sector strength on bounce attempt -Update- -Technical- | |
| Outperforming the S&P as it lifts slightly off support (see 10:20, 10:08) are Semi SMH, Retail XRT, Internet HHH, Housing XHB, REITs IYR, Gold Miners GDX, Coal KOL, Steel SLX, Materials XLB, Energy XLE. | ||
| 10:24 | TRV Dow (INDU) leaders & laggards moving through today's 1st hour of trading -Technical- | |
| INDU Best % Performers: TRV +1.25%, CSCO +1%, DD +1%, INTC +1%, AXP +.5%, MSFT +.75% INDU Worst % Performers: GE -2%, BA -2%, CVX -1.25%, KFT -1%, MMM -1%, UTX -1%, DIS -1% NYSE TRIN @ +.75 NYSE A/D @ -1445 |
||
| 10:20 | SPY S&P vacillating near support but no interest evident yet -Update- -Technical- | |
| As noted in The Technical Take the high TRIN close yesterday suggests potential for a near term bounce attempt even if some follow through pressure developed. The S&P has held near first level supports highlighted (1056/1054, session low 1055) but interest has been minimal. Intraday the first steps to improving the bias for the S&P would be a breach of 1061/1062 and the more important 1066/1067 zone. | ||
| 10:08 | SPY Choppy weaker bias with S&P and Nasdaq testing first level supports -Update- -Technical- | |
| The bias has been weaker with only limited bounce attempts leaving the S&P and Nasdaq back near first level supports mentioned in The Technical Take at 2114/2111 Nasdaq (session low 2113), 1056/1054 S&P (session low 1055). | ||
| 10:06 | XLE Energy Select Sector ETF slides to lows here as well as price probes rising 200-day SMA support @ 53.30 (53.41 -.82) -Update- -Technical- | |
| XLE -1.5% vs SPX -.65% | ||
| 10:00 | SPY Minor new session lows for stock indices but pressure contained thus far -- Dow -44, S&P -4.4, Nasdaq -7.2 -Update- -Technical- | |
| 09:54 | OIH Oil Service HOLDRS Trust continues to weaken, hovering modestly above its 200 day ema at 115.05-- session low 115.44 (115.44 -1.34) -Technical- | |
| BHI, BJS, CAM, DO, ESV, HAL, NBR, NE, NOV, RDC, RIG, SII, SLB, TDW, WFT. | ||
| 09:51 | TECHX Transports Index -TRAN- does not participate in bounce, slips under yesterday's low and its 200 day ema at 3813/3809 (3800 -13) -Technical- | |
| 09:45 | IYR iShares DJ Real Estate & ICF REITS ETF show some early recovery strength (43.15 +.38) -Technical- | |
| IYR +1%, ICF +1% vs. SPX +.10% | ||
| 09:45 | SPY Drop just modestly under yesterday's low finds some buy side interest -- Dow +2.2, S&P +0.9, Nasdaq +2.7 -Update- -Technical- | |
| Seeing early relative strength in Finance XLF +1%, Reg Bank KRE +2.2%, Bank KBE +1.3%, REITs IRY +1%, Materials XLB +0.6%. | ||
| 09:42 | XLE Energy Select Sector pulls back near its early Oct gap top at 53.83 and rebounds -- session low 53.75 (54.09 -0.14) -Technical- | |
| It is notable that the lower end of this gap (53.34) lines up with the 200 day sma (53.31). | ||
| 09:36 | TECHX IYE energy ETF probes session lows into 200 day- SMA rising support here @ 31.41 (31.40 -.21) -Technical- | |
| 09:36 | SPY Stock indices falter after limited opening upticks -- Dow -30, S&P -1.7, Nasdaq +1.4 -Update- -Technical- | |
| 09:34 | HUM Humana gaps down, holding above its 50 day sma 45.52 -- session low 45.65 (45.87 -1.30) -Technical- | |
| 09:33 | NKE Nike shares dip to opening lows with price probing 4 month range low resistance surrounding the 62~61.75 key support floor (62.03 -.06) -Technical- | |
| LoD @ 62 | ||
| 09:25 | ONP Orient Paper announces unaudited preliminary results for FY09; revenue increased 57% y/y to $102.1 mln (no estimate); reaffirms 2010 net income guidance (9.95 ) | |
| Co announces unaudited preliminary results for the year ended December 31, 2009. Total revenue increased 57%, to approximately $102.1 mln from $65.2 million in the year ended Dec. 31, 2008. Full year 2009 unaudited net income was approximately $12.5 mln, or unaudited $1.03 per diluted share, up 43% from $8.8 mln, or $0.81 per diluted share, for the year ended Dec. 31, 2008. Co states, "In fiscal 2009, demand outpaced our production capacity, which resulted in a 57% increase in revenue. Our profitability significantly increased in the full year of 2009, attributable to growth in repeat orders from our current customer base, as well as the addition of new clients. We remain confident that we will continue to achieve strong business growth in 2010, and are confident we will achieve our make good guidance of $18.0 million in net income in fiscal 2010." | ||
| 09:21 | On The Wires | |
| Bank of America (BAC) issued its Q4 Lending & Investing Initiative Report, noting the extension of more than $758 billion in credit during 2009, including nearly $180 billion during the fourth quarter... Accuray (ARAY) announced that more than 12,000 courses of lung cancer treatment have been completed with CyberKnife radiosurgery. | ||
| 09:20 | ASR Grupo Aeroportuario Del Sureste says total passenger traffic for Jan 2010 decreased by 4.6% when compared to Jan 2009 (47.74 ) | |
| 09:10 | MPR Met-Pro Corp's environmental air solutions business unit receives equipment orders totaling in excess of $1.0 mln (9.19 ) | |
| 09:01 | EPL Energy Partners increases FY10 production guidance; borrowing base under $125 mln Senior Secured Revolving Credit Facility has been reaffirmed (8.62 ) | |
| Co reports that it expects to exceed 4Q09 production guidance and has increased its full year 2010 production guidance. EPL also announced its borrowing base under its $125 mln Senior Secured Revolving Credit Facility has been reaffirmed. As previously announced, the company had three rig operations underway in 4Q09 on the Gulf of Mexico shelf. The operations on all three wells, which were completed just prior to or after the end of 2009, were successful and the production from the program significantly enhanced 4Q09 production averages and expectations for 2010 production averages. As a result, the company estimates its 4Q09 production was approximately 13,700 barrels of oil equivalent per day, slightly above the production guidance given for 4Q09 of 12,500 to 13,500 boe per day. The company also estimated that 1Q10 production should average between 14,000 and 16,000 boe per day. Additionally, the company increased its full year 2010 production guidance to 13,000 to 15,000 boe per day from the previous range of 12,500 to 13,500 boe per day. | ||
| 08:57 | SPY E~mini index futures post positive results now & with fair value calculations post even stronger gains, led by the NQ e~mini -Technical- | |
| ES +1.50 NQ +8.25 YM +17 |
||
| 08:36 | On The Wires | |
| Regenerex (RGN) announces that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tb4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. No effects related to muscle function or fibrosis and no adverse reactions were observed in the mice... ZOLL Medical Corporation (ZOLL) announces that SAMU Brasilia has equipped its ambulances with the AutoPulse Non-Invasive Cardiac Support Pump. SAMU Brasilia has installed AutoPulse units in its fleet of ambulances, one for each vehicle plus four spare training boards, in a contract valued at $500,000 (U.S.). The AutoPulse was granted health clearance in January 2009 and is the only automatic chest compression system available for sale in Brazil. | ||
| 08:35 | SPY E~minis see some upside momentum here & trade @ the best levels since 2:00a.m. ET here, NQ e~mini the relative strength leader vs. peers -Technical- | |
| ES -2.50 NQ now +3.75 |
||
| 08:32 | DMAN Demandtec announces distribution of stock by Crosspoint Venture Partners (6.00 ) | |
| Co announces that after the close of stock market trading on Feb 4, 2010, it received notice from James Dorrian, a managing member of Crosspoint Venture Partners 2000, that two of Crosspoint's venture funds, Crosspoint Venture Partners 2000, L.P. and Crosspoint Venture Partners 2000, had distributed to its limited and general partners an aggregate of approximately 6.0 mln shares of DemandTec's common stock after market close on Feb. 4, 2010. | ||
| 08:32 | NNN National Retail Properties misses by $0.02, beats on revs (19.96 ) | |
| Reports Q4 (Dec) funds from operations of $0.36 per share, $0.02 worse than the First Call consensus of $0.38; revenues rose 0.5% year/year to $57.8 mln vs the $55.9 mln consensus. "NNN remains well positioned and our previously issued 2010 guidance is not impacted by the non-cash impairments taken this quarter. Our high quality net leased retail portfolio is 96.4% occupied and has remained at least 96% leased for the last seven years. Our balance sheet is extremely strong which will allow us to take advantage of acquisition opportunities as they become available. While the acquisition volume has not been robust, we are encouraged with the quality of the opportunities that we are seeing." | ||
| 08:31 | SPY E~mini index futures near GLOBEX lows but hold in very active & illiquid trade following Jan. Nonfarm payrolls data -Technical- | |
| ES -8.5 NQ -7.50 YM -71 |
||
| 08:31 | TEVA Teva Pharm announces settlement in principle regarding certain drug pricing lawsuits; will record a charge of ~$315 mln in 4Q09 results (57.92 ) | |
| Co announces that several of its subsidiaries in the United States reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys, on behalf of the United States, Texas, Florida, and California under federal and state False Claims Acts. The cases, which are pending in federal and state courts, generally allege that the prices reported by pharmaceutical companies caused governments to pay inflated reimbursements for drugs under Medicaid or other programs. Teva denies the allegations. Upon execution of definitive settlement documents and certain government and court approvals, the settlement will resolve a lawsuit relating to federal contributions to all state Medicaid programs and claims of Texas, Florida, and California relating to their Medicaid programs. The settlement will eliminate the majority of the alleged damages asserted against Teva in the various drug pricing litigations. Teva will record a charge of approximately $315 mln in its fourth quarter, 2009 results. This charge includes both the settlement in principle and a reserve for the remaining drug pricing lawsuits to which Teva is a party. | ||
| 08:27 | ECONX Reminder: Employment Report is out in 3 minutes... DJ futures -39, S&P futures -5 | |
| 08:16 | ECONX Reminder: Jobs report due out in about 14 min at 8:30ET | |
| 08:08 | AXL American Axle beats by $0.02, reports revs in-line; guides FY10 revs below consensus (43.53 ) | |
| Reports Q4 (Dec) earnings of $0.14 per share, excluding multiple items, $0.02 better than the First Call consensus of $0.12; revenues fell 7.8% year/year to $464 mln vs the $459.5 mln consensus. Co issues downside guidance for FY10, sees FY10 revs of $1.9-$2.1 bln vs. $2.18 bln consensus. Co expects to be profitable and generate EBITDA in the range of 12% to 15% of sales in 2010. AAM expects cash payments for restructuring costs to range from $40-$50 mln in 2010. These payments relate primarily to AXL's remaining obligations under hourly and salaried attrition programs and the Buydown Program for UAW represented associates at AAM's Detroit, Michigan; Three Rivers, Michigan; and Cheektowaga, New York manufacturing facilities. AXL's updated 2010 outlook is based on the assumption that the U.S. Seasonally Adjusted Annual Rate of light vehicle sales increases from approximately 10.4 mln vehicle units in 2009 to a range of 11- 11.5 mln vehicle units in 2010. | ||
| 08:08 | HA Hawaiian Airlines reports January statistics; RPMs increased 2.2% year/year; load factor increased 3.9 pts year/year (6.08 ) | |
| Co announces that RPMs increased to 661,560 in January 2010 from 647,616 in January 2009, a 2.2% increase. Load factor increased 3.9 pts to 82.2% in January 2010 from 78.3% in January 2009. ASMs decreased to 804,896 from 827,302, a decrease of 2.7% and PAX increased to 668,737 in January 2010 from 637,946 January 2009, an increase of 4.8%. |
||
| 08:04 | SEP Spectra Energy LP misses by $0.06, beats on revs (29.32 ) | |
| Reports Q4 (Dec) earnings of $0.39 per share, $0.06 worse than the First Call consensus of $0.45; revenues rose 57.2% year/year to $52.2 mln vs the $49.4 mln consensus. The increase in net income and earnings per limited partner unit for the quarter resulted primarily from the $294.5 million acquisition of Ozark Gas Transmission and Ozark Gas Gathering in May 2009 and the strong performance across Spectra Energy Partners' other operations. Spectra Energy Partners is also announcing its 2010 financial outlook which includes estimated cash available for distribution of $175 million and estimated expansion capital expenditures of $60 million. | ||
| 08:03 | PSMT PriceSmart announced that for the month of Jan 2010, net sales increased 9.2% to $106.4 mln (20.02 ) | |
| Co announced that for the month of January 2010, net sales increased 9.2% to $106.4 million from $97.4 million in January a year earlier. For the five months ended January 31, 2010, net sales increased 5.7% to $567.1 million from $536.7 million in the same period last year. There were 26 warehouse clubs in operation at the end of January 2010 compared to 25 warehouse clubs in operation in January 2009. For the four weeks ended January 24, 2010, comparable warehouse sales for the 26 warehouse clubs open at least 12 full months increased 5.8% compared to the same four-week period last year. For the twenty-one week period ended January 24, 2010, comparable warehouse sales increased 1.9% compared to the comparable twenty-one week period a year ago. | ||
| 08:01 | AVII AVI BioPharma drug candidate AVI-5038 receives European Orphan Drug Designation for duchenne muscular dystrophy (1.42 ) | |
| The co announces that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic muscle-wasting disease caused by failure to produce dystrophin. The orphan drug designation potentially may provide AVI up to 10 years of market exclusivity if the drug candidate is approved for marketing in the European Union (EU). AVI-4658, another drug being developed by AVI for DMD, received European orphan drug designation in 2008, and also potentially may receive up to 10 years of marketing exclusivity if approved in the EU. | ||
| 08:01 | ZN Zion Oil & Gas to resume operations on its Ma'anit-Rehoboth #2 Well (5.00 ) | |
| The co announces that the Company is mobilizing its drilling rig, currently situated at the Elijah #3 well, to resume production testing operations on the Ma'anit-Rehoboth #2 well as soon as possible within approximately two weeks. | ||
| 08:01 | TSTC Telestone Tech reaffirms FY09 revs of $70 mln (13.89 ) | |
| Co reaffirms guidance for 2009, sees revenue of $70 mln (no estimates). "The pace of network installations for the nationwide 3G roll-out accelerated significantly during 2009," opened Chairman and CEO, Mr. Han Daqing. "The fourth quarter of 2009 was the largest contributor of our revenue for the year and consistent with our expectations. We are confident in achieving our revenue guidance of $70 mln for 2009, which will be a record for our company. We also made further progress during the quarter in collecting long-term receivables from our previous customers who were subsequently absorbed by the remaining "Big 3" Wireless Carrier." | ||
| 08:01 | FOLD Amicus Therapeutics Board of Directors names Chief Executive Officer John Crowley Chairman of the Board (3.61 ) | |
| The co announces that its Board of Directors has elected John Crowley as Chairman of the Board in addition to his current role as Chief Executive Officer (CEO), effective immediately. Mr. Crowley will succeed Donald Hayden, Jr., who will become the Lead Independent Director of the Board. | ||
| 08:01 | ARTG Art Technology prices a public offering of 25,000,000 shares of its common stock at $3.50 per share (3.73 ) | |
| 07:54 | COMDX Natural gas trades to its best levels of the morning at $5.564; currently higher by 12.2 cents to $5.538 | |
| 07:50 | AIG American Intl: ILFC CEO Steven Udvar-Hazy to retire (22.59 ) | |
| The co and International Lease Finance Corporation (ILFC) announce that Steven Udvar-Hazy will retire as director and chief executive officer of ILFC, effective February 5, 2010. The ILFC Board is considering the long-term management of ILFC, and President John Plueger will succeed Mr. Udvar-Hazy as acting CEO. Mr. Benmosche said that AIG expects a smooth transition. Mr. Plueger has worked at ILFC for 23 years and has served as its President and Chief Operating Officer since 1995. | ||
| 07:48 | BPL Buckeye Partners beats by $0.11, beats on revs (55.50 ) | |
| Reports Q4 (Dec) earnings of $1.03 per share, excluding $0.14 in special items, $0.11 better than the First Call consensus of $0.92; revenues rose 9.7% year/year to $579 mln vs the $441.3 mln consensus. Buckeye also announced today that its general partner, Buckeye GP LLC, declared a cash distribution of $0.9375 per LP unit for the quarter ended December 31, 2009 (up 5.6% YoY). "Despite lower volumes in our Pipeline Operations and Terminalling and Storage segments, we generated an 18 percent increase in Adjusted EBITDA during the fourth quarter of 2009 compared to the same quarter in 2008. We continue to identify opportunities to grow and strengthen our business. In mid-November 2009, we completed the previously announced acquisition of 310 miles of refined petroleum products pipelines and three refined petroleum products terminals from ConocoPhillips and integrated these strategic assets into our business." | ||
| 07:45 | BTIM BioTime, Inc. reported recently-released results from an independent study evaluating the use of Hextend (5.29 ) | |
| Co reported recently-released results from an independent study evaluating the use of Hextend in hemodynamically unstable trauma patients. The study reported that initial resuscitation with Hextend was associated with no obvious coagulopathy and reduced mortality compared to fluid resuscitation without Hextend. Results of the study showed that overall mortality for the patients treated with Hextend was significantly lower at 5.2 percent compared to 8.9 percent (p=0.0035) for the patients receiving fluid resuscitation without Hextend. Additionally, similar benefits were seen in penetrating injuries (p=0.0016) and in those severely injured. | ||
| 07:37 | TSN Tyson Foods beats by $0.24, reports revs in-line (13.99 ) | |
| Reports Q1 (Dec) earnings of $0.42 per share, $0.24 better than the First Call consensus of $0.18; revenues rose 1.7% year/year to $6.63 bln vs the $6.58 bln consensus. Co states that, "We expect seasonal demand will improve as we get further into fiscal 2010, and we expect the pricing environment to improve aided by cold storage inventories and pullet placements which are down relative to the levels we have seen over the last several years. We also currently expect to see grain costs down as compared to fiscal 2009. Additionally, we will continue to focus on making operational improvements to help maximize our margins." | ||
| 07:37 | KELYA Kelly Services beats by $0.29, beats on revs (13.25 ) | |
| Reports Q4 (Dec) earnings of $0.06 per share, excluding 29 cent restructuring charge, $0.29 better than the First Call consensus of ($0.23); revenues fell 6.6% year/year to $1.19 bln vs the $1.05 bln consensus. "We look forward to 2010, and will focus on maximizing profitability across all operations; accelerating growth of higher-margin Professional & Technical disciplines and outsourcing and consulting services; winning new business; and helping our customers manage their ever-changing workforce needs." | ||
| 07:33 | LRN K12 beats by $0.17, misses on revs; guides FY10 revs in-line (19.11 ) | |
| Reports Q2 (Dec) earnings of $0.32 per share, $0.17 better than the First Call consensus of $0.15; revenues rose 20.1% year/year to $93.2 mln vs the $95.1 mln consensus. Co issues in-line guidance for FY10, sees FY10 revs of $380-$390 mln vs. $384.55 mln consensus. Co sees FY10 operating income of approximately $27 million to $31 million and EBITDA of approximately $56 million to $60 million. In addition, the company is forecasting for fiscal year 2010: Net income-K12 Inc. of approximately $14.6-$17.1 mln; Depreciation and amortization of approximately $28-$30 mln; Non-cash stock compensation expense of approximately $6.0- $6.5 mln; Interest expense, net of interest income of approximately $1.0-$1.2 mln. | ||
| 07:32 | TE TECO Energy reports EPS in-line, misses on revs; guides FY10 EPS in-line (15.17 ) | |
| Reports Q4 (Dec) earnings of $0.25 per share, in-line with the First Call consensus of $0.25; revenues fell 0.6% year/year to $765 mln vs the $906 mln consensus. Co issues in-line guidance for FY10, sees EPS of $1.20-1.35 vs. $1.31 consensus. "We're seeing some early signs of an economic recovery in Florida, particularly in the housing market, but we expect 2010 to be another challenging year for the State's economy. Our unregulated coal and Guatemalan operations are well-positioned to deliver improved results in 2010 as a result of their 2009 efforts." | ||
| 07:12 | TM Toyota Motor: S&P places Toyota and group suppliers on watch negative (71.78 ) -Update- | |
| Standard & Poor's Ratings Services today placed its 'AA' long-term corporate credit and senior unsecured debt ratings on Japan-based automaker Toyota Motor Corp. (Toyota) and a number of related entities, including Toyota Financial Services Corp. (TFS), Toyota Finance Corp., and Toyota Motor Credit Corp. (TMCC). We also placed our long-term corporate credit ratings on Toyota group suppliers, Denso Corp. (Denso), Aisin Seiki Co. Ltd. (Aisin), and Toyota Industries Corp. (Toyota Industries) on CreditWatch with negative implications, as well as our 'A-1+' short-term rating on Toyota Industries. At the same time, we affirmed our short-term ratings on Toyota, Denso, and Aisin. The CreditWatch placements reflect Standard & Poor's increased concern over the potential negative impact on Toyota's business risk profile of unfolding developments related to recent quality-related issues. A series of Toyota's recent quality-related issues, which started with unintended acceleration caused by non-genuine floor mats and followed by the January recall of the acceleration pedals, has now expanded to include negative publicity over customer complaints about the brake system for the Prius hybrid model, particularly in Japan and the U.S. | ||
| 07:04 | AIV Apt Inv & Mgt reports EPS in-line, beats on revs; guides Q1 FFO below consensus; guides FY10 FFO in-line (15.26 ) | |
| Reports Q4 (Dec) funds from operations of $0.36 per share, excluding non-recurring items, in-line with the First Call consensus of $0.36; revenues fell 0.5% year/year to $302.8 mln vs the $295.7 mln consensus. Co issues downside guidance for Q1, sees FFO of $0.26-$0.30 vs. $0.32 consensus. Co issues in-line guidance for FY10, sees FFO of $1.25-$1.35 vs. $1.26 consensus. | ||
| 07:02 | BPO Brookfield Properties beats by $0.11, beats on revs (12.21 ) | |
| Reports Q4 (Dec) funds from operations of $0.43 per share, $0.11 better than the First Call consensus of $0.32; revenues rose 14.1% year/year to $816 mln vs the $548 mln consensus. Co also said "We are beginning to see positive signs within the office industry, and given our high-quality tenant base, our 95% occupancy rate and our low near-term lease rollover exposure, we are well positioned to benefit as the economic recovery takes hold." | ||
| 06:39 | S&P futures vs fair value: -5.70. Nasdaq futures vs fair value: -2.30. | |
| 06:39 | Asian Markets | |
| Nikkei...10057.09...-298.90...-2.90%. Hang Seng...19665.08...-676.60...-3.30%. | ||
| 06:39 | European Markets | |
| FTSE...5051.03...-88.20...-1.70%. DAX...5453.69...-80.80...-1.50%. | ||
| 06:36 | AON Aon beats by $0.15, beats on revs (38.81 ) | |
| Reports Q4 (Dec) earnings of $0.96 per share, excluding non-recurring items, $0.15 better than the First Call consensus of $0.81; revenues rose 8.8% year/year to $2.07 bln vs the $1.96 bln consensus, due to a 6% increase from foreign currency translation and a 5% increase from acquisitions, primarily Benfield, net of dispositions, partially offset by a $24 million or 63% decline in investment income. "Our fourth quarter results reflect solid operational performance across both Brokerage and Consulting. On an adjusted basis, total pretax margin increased 190 basis points and EPS from continuing operations increased 20 percent, despite difficult economic conditions and a 63 percent decline in investment income." | ||
| 06:34 | CAGC China Agritech announces 2 for 1 forward stock split effective February 1, 2010 (27.46 ) | |
| 06:33 | VVI Viad Corp beats by $0.08, reports revs in-line (18.95 ) | |
| Reports Q4 (Dec) loss of $0.35 per share, $0.08 better than the First Call consensus of ($0.43); revenues fell 17.3% year/year to $170.2 mln vs the $171.5 mln consensus. For the first quarter, Viad's loss per share before other items is expected to be in the range of $0.20 to $0.05. This compares to first quarter 2009 income before other items of $0.15 per share. Revenue is expected to be in the range of $205 mln to $220 mln as compared to $240.9 mln in the 2009 first quarter. Segment operating results are expected to be in the range of a loss of $5 mln to breakeven as compared to income of $6.7 mln in 2009. The declines from 2009 are expected to be driven primarily by expected declines in tradeshow marketing spend and negative show rotation of approximately $5 million. Paul B. Dykstra, chairman, president and chief executive officer, said, "Although the general economy is beginning to show signs of improvement, the trade show industry lags macro economic trends. As evidenced by our strong results in 2008, we were slow to follow into the recession, and we expect to lag the broader economic rebound. While we experienced some stabilization of same-show revenue declines during late 2009, we anticipate another challenging year in 2010 with continued pressures on trade show and retail marketing spending. | ||
| 06:25 | MD MEDNAX beats by $0.02; guides Q1 EPS in-line (57.01 ) | |
| Reports Q4 (Dec) earnings of $1.00 per share, excluding non-recurring items, $0.02 better than the First Call consensus of $0.98. MEDNAX's margin improvement was largely attributable to lower practice salaries and benefits expense, as a percent of net patient service revenue, resulting from the mix of practices acquired by the co during the previous 12 months as well as revenue growth at same-unit practices that generated operating efficiencies for the period. Co issues in-line guidance for Q1, sees EPS of $0.78-0.84 vs. $0.84 consensus. This outlook anticipates a range for same-unit NICU patient volume of 1% lower to as much as 1% higher for the 2010 first quarter, when compared with the 2009 first quarter, as well as an assumption that the percentage of services reimbursed under government programs for the 2010 first quarter will be as much as one percentage point higher to as much as one percentage point lower than for the 2009 fourth quarter. MEDNAX's outlook anticipates contributions from practice acquisitions within its neonatal, maternal-fetal and pediatric cardiology physician services to contribute to 2010 first quarter earnings. | ||
| 06:05 | AET Aetna misses by $0.02, reports revs in-line; guides FY10 EPS below consensus (29.23 ) | |
| Reports Q4 (Dec) earnings of $0.40 per share, excluding non-recurring items, $0.02 worse than the First Call consensus of $0.42; revenues rose 9.0% year/year to $8.7 bln vs the $8.65 bln consensus. The decrease in operating EPS from the prior-year quarter reflects a lower Commercial underwriting margin, lower operating earnings in the Group Insurance business and an increase in pension expense partially offset by the impact of a lower number of outstanding shares. The lower Commercial underwriting margin was due to a significant increase in Commercial medical costs which was partially offset by an increase in health care premiums. The lower Group Insurance operating earnings were due to lower disability underwriting margins from increased long-term disability reserves. Co issues downside guidance for FY10, sees EPS of $2.55-2.65 vs. $2.83 consensus. | ||
| 05:57 | KFT Order by Kraft Foods for Cadbury - notice of delisting and related matters (28.39 ) | |
| Co announced on February 2, 2010 that all of the conditions to its recommended final offer had been satisfied or waived and, accordingly, the offer was wholly unconditional. As Kraft Foods is in receipt of valid acceptances in respect of at least 75%. of the existing issued share capital of Cadbury (CBY), Cadbury confirms that the 20 Business Days' notice period for the cancellation of the listing of Cadbury Shares on the Official List and the trading on the London Stock Exchange for listed securities has commenced. | ||
| 05:14 | BRKS Brooks Automation misses by $0.02, beats on revs (8.52 ) | |
| Reports Q1 (Dec) loss of $0.02 per share, excluding non-recurring items, $0.02 worse than the First Call consensus of ($0.00); revenues rose 44.7% year/year to $106.2 mln vs the $94.1 mln consensus. | ||
| 03:35 | SIMG Silicon Image misses by $0.01, reports revs in-line; guides Q1 revs below consensus (2.29 ) | |
| Reports Q4 (Dec) loss of $0.07 per share, excluding non-recurring items, $0.01 worse than the First Call consensus of ($0.06); revenues fell 4.2% year/year to $35.6 mln vs the $35.5 mln consensus. Co issues downside guidance for Q1, sees Q1 revs of $30.0-32.0 mln vs. $34.47 mln consensus. Co sees gross margin of 54.0-55.0%. | ||
| 03:32 | BLKB Blackbaud beats by $0.03, beats on revs (22.28 ) | |
| Reports Q4 (Dec) earnings of $0.27 per share, excluding non-recurring items, $0.03 better than the First Call consensus of $0.24; non-GAAP revenues fell 2.5% year/year to $79.9 mln vs the $78.7 mln consensus. | ||
| 03:27 | WY Weyerhaeuser misses by $0.14, beats on revs (40.39 ) | |
| Reports Q4 (Dec) loss of $0.52 per share, excluding non-recurring items, $0.14 worse than the First Call consensus of ($0.38); revenues fell 18.1% year/year to $1.46 bln vs the $1.37 bln consensus. 4Q09 earnings from operations were lower primarily due to the co's decision to defer additional harvest, lower sales of non-strategic timberlands and higher logging, trucking and road costs. These reductions were partially offset by an increase in log sales realizations. Excluding the effect of non-strategic land sales, Weyerhaeuser expects first quarter operating earnings from the segment to be comparable to fourth quarter primarily due to improved log sales realizations offset by higher costs. | ||
| 02:00 | On The Wires | |
| Omega Healthcare Investors (OHI) announces the pricing of a private placement of $200 mln aggregate principal amount of 71/2% senior notes due 2020... Phoenix Technologies (PTEC) announces it has filed a patent infringement lawsuit against DeviceVM... Pfizer (PFE) and DxS (a wholly owned subsidiary of QIAGEN (QGEN)) announce that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme; financial terms of the diagnostic agreement have not been disclosed... The Gatorade Company, a division of PepsiCo (PEP), is expanding on its hydration expertise and staking out new ground by delivering a broader product line to help address the sports performance needs of more athletes. |
||
| 01:56 | SYT Syngenta reports FY09 results (50.47 ) | |
| Co reports FY09 sales of $11 bln, up 1% at constant exchange rates. EBITDA margin was maintained at 21.6%. Seeds margin was 9.5%. Co reports EPS of $15.76, 3% lower. EPS was $14.62 after restructuring and impairment, unchanged. Free cash flow was $580 mln. Crop Protection sales excluding Professional Products were 1.0% lower compared with a record 2008. | ||
| 01:40 | ARG Air Products offers to acquire Airgas for $60.00/share in cash (43.53 ) | |
| Air Products (APD 73.69) announces that it has made an offer to acquire Airgas for $60.00 per share in cash. The offer was made in a letter to Airgas' Board of Directors yesterday after the CEOs of the two companies had previously discussed Air Products' interest in acquiring Airgas and after Air Products had made two written offers, and these offers and Air Products' requests to discuss them were rejected by Airgas. The total value of the transaction is approx $7.0 bln, including $5.1 bln of equity and $1.9 bln of assumed debt. The acquisition is expected to be immediately accretive to Air Products' EPS on both a GAAP and cash basis, excluding expected one-time costs. | ||
|
||
| 18:33 | EDE Empire District Elec misses by $0.03 (18.04 -0.34) | |
| Reports Q4 (Dec) earnings of $0.22 per share, $0.03 worse than the First Call consensus of $0.25. | ||
| 18:29 | SSTI Silicon Storage reports Q4 EPS of $0.02 vs. ($0.38) in the prior year; revs grew 2.2% to $72.9 mln (2.84 -0.01) | |
| 18:19 | RYN Rayonier credit rating affirmed by Standard & Poor's; outlook revised to positive (40.76 -1.61) | |
| Co announced that Standard & Poor's (S&P's) debt rating service affirmed the co's 'BBB' corporate credit rating and revised its outlook to positive from stable. The S&P Research Update, dated Feb. 3, cited RYN's attractive business mix as enabling the co to continue to generate relatively stable earnings and cash flow, even during a severe housing downturn. | ||
| 17:53 | ESS Essex Property misses by $0.02; guides FY10 FFO in-line (77.66 ) | |
| Reports Q4 (Dec) funds from operations of $1.16 per share, $0.02 worse than the First Call consensus of $1.18. Co issues in-line guidance for FY10, sees FFO of $4.60-4.90 vs. $4.67 consensus. | ||
| 17:52 | AXE Anixter International announces share repurchase program to purchase up to 1 mln of its outstanding shares (38.74 -1.56) | |
| Anixter currently has ~34.5 mln shares outstanding. | ||
| 17:18 | RAH Ralcorp Holdings beats by $0.17, reports revs in-line (61.05 -0.64) | |
| Reports Q1 (Dec) earnings of $1.20 per share, excluding $0.01 in non-recurring items, $0.17 better than the First Call consensus of $1.03; revenues rose 2.4% year/year to $991.9 mln vs the $988.5 mln consensus. Total segment profit contribution grew 19% excluding the incremental amounts from Harvest Manor Farms (Harvest), acquired March 20, 2009 and included in the Snacks, Sauces & Spreads segment. | ||
| 17:17 | DNB Dun & Bradstreet reports EPS in-line, beats on revs (77.74 -1.21) | |
| Reports Q4 (Dec) earnings of $1.75 per share, in-line with the First Call consensus of $1.75; revenues fell 2.3% year/year to $463.7 mln vs the $459 mln consensus. D&B today announced that its Board of Directors has declared an increased quarterly cash dividend to $0.35 per share, up from D&B's prior quarterly dividend payout of $0.34 per share. D&B today provided the following financial guidance for the full year 2010: Core revenue growth of 1 percent to 3 percent, before the effect of foreign exchange; Operating income of down 2 percent to up 2 percent, before non-core gains and charges; Diluted EPS growth of 1 percent to 6 percent, before non-core gains and charges; and free cash flow of $240 million to $270 million, which excludes the impact of legacy tax matters but includes the new strategic technology investment. | ||
| 17:11 | PVA Penn Virginia anounces records for proved reserves and annual production; provides operational update (23.55 -1.27) -Update- | |
| Co announced record levels of proved oil and gas reserves and production and provided an update of its oil and gas operations, including full-year and fourth quarter 2009 results, guidance and liquidity. Operational results for its oil and gas segment for the year ended December 31, 2009 included the following: Record year-end proved oil and gas reserves of 942 bln cubic feet of natural gas equivalent (Bcfe), an increase of three percent over 916 Bcfe at year-end 2008; Record oil and gas production of 51.0 Bcfe, an increase of 9% over 46.9 Bcfe in 2008. Oil and gas capital expenditures of ~$172 mln, including ~$143 mln for drilling and completion activities to drill 32 (20.7 net) wells, with a 96% success rate. For 2010, Production guidance of 47.0-51.0 Bcfe, unchanged as compared to previous guidance, and representing a 6-13% increase over 2009 production of 45.2 Bcfe, pro forma for production from Gulf Coast assets that were sold in January 2010; Oil and gas capital expenditures guidance of $375-425 mln, as compared to a range of $300-400 mln of previous guidance. | ||
| 17:06 | MTX Minerals Tech beats by $0.11, beats on revs (47.14 -0.35) | |
| Reports Q4 (Dec) earnings of $0.62 per share, excluding non-recurring items, $0.11 better than the First Call consensus of $0.51; revenues rose 6.7% year/year to $256.2 mln vs the $234.9 mln single-analyst est. | ||
| 17:05 | MAA Mid-America Aptmt beats by $0.04, beats on revs; guides Q1 FFO in-line; guides Q2 (Jun) FFO in-line; guides FY10 FFO in-line (46.75 -0.61) | |
| Reports Q4 (Dec) funds from operations of $0.92 per share, $0.04 better than the First Call consensus of $0.88; revenues rose 1.4% year/year to $95.2 mln vs the $93 mln consensus. Physical occupancy for the same store portfolio ended the year at a solid 95.1%, which is 1.7% ahead of the same period in 2008. Same store net collection loss remained historically low at only 0.4% of net potential rent during the fourth quarter of 2009. Co issues in-line guidance for Q1, sees FFO of $0.86-$0.96 vs. $0.92 consensus. Co issues in-line guidance for Q2 (Jun), sees FFO of $0.84-$0.94 vs. $0.91 consensus. Co issues in-line guidance for FY10, sees FFO of $3.45-$3.65 vs. $3.54 consensus. | ||
| 16:52 | JBHT JB Hunt Trans increases qtrly dividend to 12 cents per share (30.29 -0.88) | |
| 16:50 | MNI McClatchy announces pricing of $875 mln of its 11.50% senior secured notes due 2017; the notes will have an issue price to the public of 98.824% (5.02 -0.31) | |
| 16:50 | MAR Marriott reinstates cash dividend (25.74 -0.77) | |
| The co announces that its board of directors has declared the issuance of a cash dividend in the amount of four cents ($0.04) per share on each share of Class A common stock outstanding of the company, payable on April 9, 2010 to shareholders of record on February 19, 2010. | ||
| 16:47 | FMC FMC Corp beats by $0.04, reports revs in-line; guides Q1 EPS in-line; guides FY10 EPS in-line (50.80 -2.03) | |
| Reports Q4 (Dec) earnings of $0.94 per share, $0.04 better than the First Call consensus of $0.90; revenues fell 2.1% year/year to $722.1 mln vs the $715.5 mln consensus. Co issues in-line guidance for Q1, sees EPS of $1.20-1.35 vs. $1.25 consensus. Co issues in-line guidance for FY10, sees EPS of $4.35-4.75 vs. $4.57 consensus. "Our fourth quarter results met our expectations. We realized continued strong performance in Agricultural Products and Specialty Chemicals. Industrial Chemicals' demand, though lower than prior year, once again improved on a sequential basis. Agricultural Products' results were primarily driven by sales gains in Latin America. Specialty Chemicals' earnings growth was the result of strong commercial performance in BioPolymer. Industrial Chemicals' results were impacted by reduced selling prices in phosphates and lower soda ash volumes. As we enter 2010, we are seeing continued sequential volume growth across our businesses." | ||
| 16:41 | AATI Advanced Analogic Tech reports EPS in-line, revs in-line; guides Q1 revs above consensus (3.49 +0.01) | |
| Reports Q4 (Dec) loss of $0.05 per share, in-line with the First Call consensus of ($0.05); revenues rose 11.8% year/year to $20.8 mln vs the $20.7 mln consensus. Co reported gross margins of 47.6% for the fourth quarter of 2009, compared to 38.0% for the fourth quarter of 2008 and 51.2% for the third quarter of 2009. Non-GAAP gross margin was 48.1% for the fourth quarter of 2009, compared to 43.3% for the fourth quarter of 2008 and 51.7% for the third quarter of 2009. The Company ended the fourth quarter of 2009 with $102.0 mln in cash, cash equivalents, and short-term investments. Co issues guidance for Q1, sees EPS of ($0.12) - ($0.10), may not be comparable to ($0.07) consensus; sees Q1 revs of $21 mln-$23 mln vs. $19.67 mln consensus. The first quarter 2010 estimates include pre-tax quarterly share-based compensation expense in the range of $1.4 to $1.6 mln | ||
| 16:40 | TSYS TeleComm Sys beats by $0.14, beats on revs (8.76 -0.27) | |
| Reports Q4 (Dec) earnings of $0.20 per share, $0.14 better than the First Call consensus of $0.06; revenues rose 14.5% year/year to $90.8 mln vs the $85.3 mln consensus. Fourth quarter 2009 results include partial-period contributions from three businesses acquired during the quarter. Their total revenue contribution was approximately $5 mln or less than 6% of the company's $90.8 mln total revenue for the quarter. Year-end total backlog was $630.8 mln, up from $450 mln at the end of last year. The increase includes the effects of businesses acquired in the fourth quarter. | ||
| 16:39 | F Ford Motor to fix brake problem on Milan, Fusion hybrids (11.06 -0.58) | |
| Co says it will fix 17,600 Mercury Milan and Ford Fusion gas-electric hybrids that can give drivers the impression the brakes have failed. The automaker says the problem occurs in transition between two braking systems and at no time are drivers without brakes. Ford decided to fix the 2010 model cars after a test driver for Consumer Reports magazine experienced the problem as he was testing a Fusion Hybrid. Ford spokesman Said Deep says braking power seems to drop away as the car makes a transition from regenerative brakes to the conventional system. Regenerative brakes capture energy from braking to help recharge a hybrid's battery. | ||
| 16:37 | NATL National Interstate increases dividend 14% to $0.08 per share (16.25 -0.59) | |
| 16:35 | NCMI National Cinemedia raises guidance for FY09 (14.23 -1.06) | |
| As mentioned at 16:36 co issues in-line guidance for Q1 (Mar), sees Q1 (Mar) revs of $76-79 mln vs. $77.45 mln First Call consensus. Co issues raises guidance for FY09 (Dec), sees FY09 (Dec) revs of $380 mln vs. $367.16 mln consensus. Co issues upside guidance for FY10 (Dec), sees FY10 (Dec) revs of $400-410 mln vs. $390.43 mln consensus. Co also sees 2009 Adjusted OIBDA to be approx $189 mln. For the first quarter of 2010, the co also expects Adjusted OIBDA to be in the range of $27 to $29 mln and FY10 adjusted OIBDA to be in the range of $194 to $204 mln. |
||
| 16:34 | HLIT Harmonic beats by $0.02, beats on revs; guides 1H10 above consensus; announces retirement of CFO (5.90 -0.17) | |
| Reports Q4 (Dec) earnings of $0.07 per share, excluding non-recurring items, $0.02 better than the First Call consensus of $0.05; revenues fell 10.5% year/year to $86.7 mln vs the $83.9 mln consensus. Co issues upside 1H10 guidance, anticipates that net sales for the first half of 2010 will be in a range of $170.0-180.0 million vs the $166.5 mln consensus. Non-GAAP gross margins and operating expenses for the first half of 2010, which exclude charges for stock-based compensation and the amortization of intangibles, are anticipated to be in a range of 48% to 49% and $66.5 to $68.5 million, respectively. Total bookings in the fourth quarter of 2009 were $107.6 million, up from $79.9 million in the third quarter. For the full year 2009, net sales were $319.6 million, compared to $365.0 million in 2008. International sales represented 50% of net sales for the fourth quarter and 49% for the full year of 2009, up from 47% and 44%, respectively, for the same periods in 2008. In 2009, the co's 10 largest customers contributed 47% of net sales, compared to 58% in 2008. CFO Dickson announces plans to retire, the search for a new CFO has begun. | ||
| 16:33 | BMI Badger Meter misses by $0.03, misses on revs (36.62 -1.04) | |
| Reports Q4 (Dec) earnings of $0.34 per share, $0.03 worse than the First Call consensus of $0.37; revenues fell 16.7% year/year to $56.4 mln vs the $59.7 mln consensus. "The federal stimulus funding is expected to be allocated by mid February and there are signs that the economy is starting to recover. Commodity costs are starting to increase, but overall, we are cautiously optimistic about 2010." | ||
| 16:32 | NCMI National Cinemedia increases 2009 Guidance and Provides 2010 Outlook (14.26 -1.06) | |
| 16:32 | HLIT Harmonic beats by $0.02, beats on revs; CFO to retire (5.90 -0.17) | |
| Reports Q4 (Dec) earnings of $0.07 per share, excluding non-recurring items, $0.02 better than the First Call consensus of $0.05; revenues rose 3.3% year/year to $86.7 mln vs the $83.9 mln consensus. Harmonic anticipates that net sales for the first half of 2010 will be in a range of $170.0 to $180.0 million, First Call consensus is $166 mln. GAAP gross margins and operating expenses for the first half of 2010 are expected to be in a range of 45% to 46% and $72.5 to $74.5 million, respectively. Non-GAAP gross margins and operating expenses for the first half of 2010, which exclude charges for stock-based compensation and the amortization of intangibles, are anticipated to be in a range of 48% to 49% and $66.5 to $68.5 million, respectively. Robin Dickson, the Company's Chief Financial Officer, has announced plans to retire. The Company has launched a search for a new CFO, and Mr. Dickson will continue to serve until the Company's search is complete and the smooth transition to a new CFO is accomplished. | ||
| 16:26 | RJET Republic Airways announces fleet simplification plan (4.79 -0.23) | |
| Co announces it will transition the regional service operated by Lynx Aviation Bombardier Q400 turboprop aircraft to Embraer 170 and 190 jet service operated by Republic Airlines. The Company will remove three Q400 turboprop aircraft from service effective April 6. Another three aircraft will be removed from service on April 19. In addition, the Company will terminate the leases of seven smaller regional jets and return them to the lessor. | ||
| 16:26 | PKI PerkinElmer beats by $0.02, beats on revs; guides FY10 EPS above consensus (19.82 -0.86) | |
| Reports Q4 (Dec) earnings of $0.43 per share, excluding non-recurring items, $0.02 better than the First Call consensus of $0.41; revenues fell 0.3% year/year to $498.3 mln vs the $479.5 mln consensus. Co issues upside guidance for FY10, sees EPS of $1.35-1.42, excluding non-recurring items, vs. $1.38 consensus. For the full year 2010, the Company forecasts a low to mid single digit increase in organic revenue relative to 2009 ($1.892 bln consensus). | ||
| 16:24 | TNL Technitrol beats by $0.01 (4.17 -0.19) | |
| Reports Q4 (Dec) earnings of $0.09 per share, excluding accelerated amortization (reported as interest expense) of capitalized fees related to amending the co's credit facility, $0.01 better than the First Call consensus of $0.08; revenues rose 3.9% year/year to $105.4 mln vs the $104.9 mln dual-analyst est. | ||
| 16:24 | SUN Sunoco misses by $0.01, beats on revs (25.67 -0.82) | |
| Reports Q4 (Dec) loss of $0.27 per share, $0.01 worse than the First Call consensus of ($0.26); revenues rose 3.8% year/year to $8.97 bln vs the $8.31 bln consensus. Sunoco's Board of Directors today declared a cash dividend for the first quarter of 2010 of $0.15 per share and the Company's management believes that Sunoco's current dividend level is sustainable under current conditions. Sunoco expects to take a pre-tax charge in the first quarter of 2010 for the loss on the sale of the polypropylene business of approximately $185 to $195 million. | ||
| 16:23 | PFWD Phase Forward reports EPS in-line, revs in-line; guides Q1 EPS below consensus, revs below consensus; guides FY10 EPS below consensus, revs below consensus (14.85 -0.34) | |
| Reports Q4 (Dec) earnings of $0.13 per share, excluding non-recurring items, in-line with the First Call consensus of $0.13; revenues rose 21.7% year/year to $58.8 mln vs the $58.7 mln consensus. Co issues downside guidance for Q1, sees EPS of $0.11-0.12, excluding non-recurring items, vs. $0.14 consensus; sees Q1 revs of $56-57.5 mln vs. $60.07 mln consensus. Co issues downside guidance for FY10, sees EPS of $0.54-0.60, excluding non-recurring items, vs. $0.63 consensus; sees FY10 revs of $240-248 mln vs. $256.51 mln consensus. Q4 Non-GAAP income from operations was $8.7 million, an increase from $7.5 million in the prior year period, representing a non-GAAP operating margin of 15%. "As we begin 2010, we expect Phase Forward to deliver solid financial results, characterized by low to mid-teen revenue growth and a continuation of the recent trend of margin expansion. With many of the visionaries and largest companies in the pharmaceutical industry further down the path from an EDC adoption perspective, it will be increasingly important for vendors to deliver a true end-to-end ICRS offering. During 2010, and even more so in future years, we expect areas complementary to EDC to be the fastest growing segments of the ICRS market. Moreover, it will be these areas along with the ability to deliver an end-to-end ICRS offering that customers will increasingly evaluate when making decisions on strategic vendor relationships. We believe Phase Forward's market share lead in EDC and status as the only true ICRS vendor at this time position the company well to sustain and potentially increase revenue growth as the market evolves toward purchases of integrated applications and end-to-end ICRS offerings | ||
| 16:22 | MPR Met-Pro Corp announces consolidation of businesses (9.19 -0.19) | |
| Co announces it has consolidated its Duall, Flex-Kleen and Met-Pro Systems business units into a single business unit, Met-Pro Environmental Air Solutions, which will remain a part of Met-Pro's Product Recovery/Pollution Control Technologies platform. "The newly-formed Met-Pro Environmental Air Solutions business unit will allow us to improve our capacity utilization, reduce our cost structure and improve our competitive positioning and profitability," stated De Hont. "We will be better able to take advantage of the many synergies that exist between the Duall, Flex-Kleen and Systems brands, allowing us the opportunity to gain market share, especially in markets where we currently have limited or no presence, and service our customers in a more effective manner. Our goal is to not only preserve, but to enhance the globally recognized Duall, Flex-Kleen and Systems brands our customers have come to know and depend upon." | ||
| 16:20 | ILMN Illumina beats by $0.09, beats on revs; reaffirms FY10 EPS below consensus, revs below consensus (36.62 -1.23) | |
| Reports Q4 (Dec) earnings of $0.29 per share, $0.09 better than the First Call consensus of $0.20; revenues rose 12.2% year/year to $180.6 mln vs the $173 mln consensus. Gross margin in the fourth quarter of 2009 was 69.5% compared to 64.4% in the comparable period of 2008. Excluding the effect of non-cash charges associated with stock compensation and the amortization of intangibles, non-GAAP gross margin was 71.2% for the fourth quarter of 2009 compared to 66.7% in the prior year period (consensus was for 68.2% gross margin). Co reaffirms guidance for FY10, sees EPS of $0.90-1.00 vs. $1.01 consensus; sees FY10 revs up 20%, equates to $799.2 vs. $802.28 mln consensus. Gross margins are expected to be in the mid to high 60s (consensus is for gross margins of 68.1%). | ||
| 16:19 | BBND Bigband Networks beats by $0.05, beats on revs; guides Q1 EPS below consensus, revs in-line; guides FY10 revs below consensus (2.83 +0.00) | |
| Reports Q4 (Dec) earnings of $0.04 per share, $0.05 better than the First Call consensus of ($0.01); revenues fell 36.4% year/year to $34.4 mln vs the $33.5 mln consensus. Co issues mixed guidance for Q1, sees EPS of ($0.03)-($0.05) vs. $0.00 consensus; sees Q1 revs of $33-35 mln vs. $34.92 mln consensus. "In fiscal year 2010, we expect revenues to grow at approximately 10% -- equates to $153.45 mln vs. $161.46 mln consensus -- despite the cautious capital spending indicated by our customers. Video is at the core of our customers' business strategy, and we believe a larger portion of capital budgets will be allocated to digital video networking over time." | ||
| 16:18 | HAIN Hain Celestial reports EPS in-line, misses on revs; guides FY10 EPS below consensus, revs below consensus (14.53 -0.86) | |
| Reports Q2 (Dec) earnings of $0.31 per share, excluding non-recurring items, in-line with the First Call consensus of $0.31; revenues fell 22.5% year/year to $242 mln vs the $253.2 mln consensus. Co issues downside guidance for FY10, sees EPS of $1.05-1.10 vs. $1.22 consensus; sees FY10 revs of $920-940 mln vs. $971.91 mln consensus. | ||
| 16:18 | BIOD Biodel reports 1Q results (3.65 -0.28) | |
| Biodel reports 1Q10 earnings of ($0.47) vs ($0.43) First Call consensus; Biodel reported revenues of $0.00 vs $0.00 First Call consensus. Research and development expenses were $8.8 mln for the three months ended December 31, 2009, compared to $8.0 mln for the same period in the prior year. The increase in research and development expenses was primarily due to regulatory, personnel and consulting expenses which were offset by reductions in clinical fees as patients completed the Phase 3 extension trials for VIAject. | ||
| 16:17 | FIS Fidelity National Information Services beats by $0.01; reaffirms FY10 EPS growth forecast (23.54 -0.45) | |
| Reports Q4 (Dec) earnings of $0.44 per share, excluding non-recurring items, $0.01 better than the First Call consensus of $0.43; adjusted revenues rose 2.7% year/year to $1.32 bln vs the $1.3 bln consensus. Co reaffirms guidance for FY10, sees adj, EPS up 17-23%, which is EPS of $1.91-2.01, excluding non-recurring items, vs. $1.97 consensus, co sees adj. FY10 revs up 2-4% YoY, which we caluculate to be FY10 adj. revs of $5.15-5.25 bln vs the $5.20 bln consensus. | ||
| 16:17 | ABCO Advisory Board misses by $0.03, beats on revs (31.88 -0.10) | |
| Reports Q3 (Dec) earnings of $0.27 per share, $0.03 worse than the First Call consensus of $0.30; revenues rose 2.7% year/year to $60.9 mln vs the $60.1 mln consensus. For calendar year 2010, we anticipate revenue to be approximately 10% higher than calendar year 2009. We expect EBITDA in a range of approximately $36 million to $41 million, and earnings per diluted share of approximately $1.20 to $1.40. For fiscal year 2011, we expect an effective tax rate of approximately 35.5% to 36.5%. | ||
| 16:17 | KLAC KLA-Tencor declares quarterly dividend of $0.15/share and resumes stock buyback program under which 9.8 mln shares are available for repurchase (28.31 -0.98) | |
| 16:16 | MTSC MTS Systems misses by $0.03, misses on revs (3.17 -0.51) | |
| Reports Q1 (Dec) earnings of $0.23 per share, $0.03 worse than the First Call consensus of $0.26; revenues fell 23.7% year/year to $89 mln vs the $91.5 mln consensus. "As we look forward, there are several aspects of our business and the market that support our cautious sense of optimism. First, overall market conditions remained relatively unchanged during the quarter and this sense of ongoing stability is reassuring. Second, the expense-reduction and efficiency initiatives implemented over the past several quarters successfully aligned our cost structure with this environment. Third, we are encouraged that our shorter-cycle Sensors segment, which was more immediately impacted by the economic downturn at its onset, is achieving margin results similar to pre-recession levels." | ||
| 16:16 | ENMD EntreMed announces it completed a registered direct offering of 3,846,154 shares of its common stock, at a purchase price of $0.65 per share, to a single accredited institutional investor (0.70 -0.08) | |
| 16:14 | SFSF SuccessFactors reports EPS in-line, beats on revs; guides Q1 EPS below consensus, revs above consensus; guides FY EPS in-line, revs in-line (15.61 -0.88) | |
| Reports Q4 (Dec) earnings of $0.01 per share, in-line with the First Call consensus of $0.01; revenues rose 27.9% year/year to $42.2 mln vs the $39.7 mln consensus. Co issues mixed guidance for Q1, sees EPS of ~$0.00 vs. $0.02 consensus; sees Q1 revs of $43-43.5 mln vs. $41.52 mln consensus. Co issues in-line guidance for FY10, sees EPS of ~$0.00 vs. $0.11 consensus; sees FY10 revs of $178-180 mln vs. $176.79 mln consensus. Co also announced they have entered into a definitive agreement under which SuccessFactors will acquire Inform. With this strategic acquisition, SuccessFactors will be the first company to offer business analytics and workforce planning as part of a comprehensive business execution software suite. Under the terms of the acquisition agreement, the co will pay $25.5 mln in cash and approx $15 mln in SuccessFactors common stock for Inform, with additional contingent consideration payable based on the fulfillment of continuing employment and the achievement of specified growth targets. The acquisition on a pro forma basis and excluding the write-down of the deferred revenue balance and any contingent consideration expense is expected to be neutral to SuccessFactors' net income. The acquisition is expected to close in Q3 2010, subject to customary closing conditions. | ||
| 16:14 | SLH Solera beats by $0.07, beats on revs; guides FY10 EPS in-line, revs in-line (32.28 -0.51) | |
| Reports Q2 (Dec) earnings of $0.54 per share, excluding non-recurring items, $0.07 better than the First Call consensus of $0.47; revenues rose 24.4% year/year to $163.3 mln vs the $156.7 mln consensus. Co issues in-line guidance for FY10, sees EPS of $1.94-2.01 vs. $1.95 consensus; sees FY10 revs of $629-632 mln vs. $630.95 mln consensus. | ||
| 16:14 | ARAY Accuray misses by $0.01, beats on revs; guides FY10 revs above consensus (5.75 -0.05) | |
| Reports Q2 (Dec) loss of $0.02 per share, $0.01 worse than the First Call consensus of ($0.01); revenues fell 0.5% year/year to $57.3 mln vs the $54.8 mln consensus. Co issues upside guidance for FY10, sees FY10 revs of $220-230 mln up from prior guidance of $215-230 mln and vs. $218.8 mln consensus. | ||
| 16:14 | ESE Esco Tech reports EPS in-line, misses on revs (31.45 ) | |
| Reports Q1 (Dec) earnings of $0.02 per share, in-line with the First Call consensus of $0.02; revenues fell 23.5% year/year to $112.7 mln vs the $122.3 mln consensus. | ||
| 16:13 | PWER Power-One beats by $0.08, beats on revs (3.10 -0.18) | |
| Co reports Q4 EPS of $0.05, $0.08 better than the ($0.03) First Call consensus; revs rose 9% year/year to $142 mln vs $114.87 mln First Call consensus. "With the increasing demand for our renewable energy and power products, we look forward to a strong year in 2010. The successful implementation of cost controls and a focus on expanding our markets enabled us to generate greater cash flow on improving margins," | ||
| 16:13 | CNW Con-way misses by $0.14, beats on revs (28.33 -0.54) | |
| Reports Q4 (Dec) net of breakeven, ex-item, $0.14 worse than the First Call consensus of $0.14; revenues fell 0.8% year/year to $1.12 bln vs the $1.08 bln consensus. Co states, "Excess capacity remains a problem for the LTL and truckload markets which continues to suppress profit recovery. It will be incumbent upon us to maintain strong liquidity and vigilant cost control while we invest prudently for the strategic needs of our business and customers going forward." | ||
| 16:12 | CTCT Constant Contact reports 4Q results; issues in-line guidance (17.42 -0.45) | |
| Constant Contact reports 4Q earnings of ($0.01) vs $0.00 First Call consensus; revs increased 43% year/year to $36.5 mln vs $36.13 mln First Call consensus. Co issues in-line guidance for 2010, sees non-GAAP EPS of $0.33 to $0.36 vs $0.36 First Call consensus. | ||
| 16:11 | OPTR Optimer Pharma announces positive results from second fidaxomicin Phase 3 study in patients with clostridium difficile infection (11.86 -0.78) | |
| Co announces positive top-line results from the second of two pivotal Phase 3 trials evaluating the safety and efficacy of fidaxomicin in patients with Clostridium difficile Infection. This study was conducted in approximately 100 clinical sites throughout North America and Europe. The Company plans to use data from this study to support submission of a New Drug Application to the FDA in the second half of 2010. The trial met the primary endpoint of non-inferiority with 91.7% of patients treated with fidaxomicin achieving clinical cure vs. 90.6% for Vancocin, the only FDA-approved therapy for CDI. Importantly, fidaxomicin also had significantly lower recurrence rates and higher global cure rates compared to Vancocin. Only 12.8% of patients treated with fidaxomicin experienced a recurrence vs. 25.3% of patients treated with Vancocin. Additionally, 79.6% of patients treated with fidaxomicin achieved a global cure versus 65.5% of patients treated with Vancocin. As in the first Phase 3 trial, fidaxomicin was well-tolerated in the study. | ||
| 16:10 | PWAV Powerwave misses by $0.02, misses on revs (1.35 -0.06) | |
| Reports Q4 (Dec) earnings of $0.01 per share, $0.02 worse than the First Call consensus of $0.03; revenues fell 20.9% year/year to $142.6 mln vs the $148.3 mln consensus. | ||
| 16:10 | MPWR Monolithic Power beats by $0.01, beats on revs; guides Q1 revs above consensus (18.98 -0.89) | |
| Reports Q4 (Dec) earnings of $0.20 per share, $0.01 better than the First Call consensus of $0.19; revenues rose 34.0% year/year to $46.5 mln vs the $45.2 mln consensus. Co issues upside guidance for Q1, sees Q1 revs of $45-$49 vs. $41.86 mln consensus. Co also sees gross margin flat to slightly down from 4Q09; Research and development and selling, general and administrative expenses between $19.2 mln and $20.6 mln; and Non-GAAP research and development and selling, general and administrative expenses between $16.0 mln and $17.0 mln. This excludes an estimate of stock-based compensation expense in the range of $3.2 mln to $3.6 mln. | ||
| 16:09 | N NetSuite reports EPS in-line, revs in-line (14.53 -0.96) | |
| Reports Q4 (Dec) earnings of $0.02 per share, in-line with the First Call consensus of $0.02; revenues rose 3.9% year/year to $43 mln vs the $43 mln consensus. NetSuite added approximately 295 new customers in the fourth quarter. "Our ten year head start in delivering cloud computing business applications bodes well for us in 2010 as companies continue to move their core business applications from 1990's style client-server offerings to NetSuite solutions that have cloud computing at their core." | ||
| 16:08 | CSCX Cardiac Science Corp accelerated the availability date to February 2010 for the AED software update; previously estimated May 2010 date (2.55 -0.22) | |
| 16:07 | SRCL Stericycle reports EPS in-line, beats on revs (52.99 -1.49) | |
| Reports Q4 (Dec) earnings of $0.55 per share, excluding non-recurring items, in-line with the First Call consensus of $0.55; revenues rose 14.4% year/year to $313.5 mln vs the $306.4 mln consensus. EPS excludes the effects of $1.8 million of after-tax transactional expenses related to acquisitions and $1.0 million of after-tax restructuring costs for our regulated returns management services business. | ||
| 16:07 | TTMI TTM Tech misses by $0.03, beats on revs; guides Q1 EPS below consensus, revs below consensus (9.77 -0.38) | |
| Reports Q4 (Dec) earnings of $0.14 per share, excluding charges related to previously announced plant closures and the Meadville Holdings transaction, $0.03 worse than the First Call consensus of $0.17; revenues fell 9.1% year/year to $149.9 mln vs the $145.4 mln consensus. Co issues downside guidance for Q1, sees EPS of $0.06-0.11 vs. $0.18 consensus; sees Q1 revs of $132-140 mln vs. $145.05 mln consensus. | ||
| 16:07 | RMD ResMed beats by $0.05, beats on revs (51.41 -0.75) | |
| Reports Q2 (Dec) earnings of $0.60 per share, $0.05 better than the First Call consensus of $0.55; revenues rose 23.4% year/year to $275.1 mln vs the $259 mln consensus. | ||
| 16:07 | LQDT Liquidity Services beats by $0.04, beats on revs; guides Q2 EPS in-line; guides FY10 EPS in-line (10.83 -0.38) | |
| Reports Q1 (Dec) earnings of $0.14 per share, excluding non-recurring items, $0.04 better than the First Call consensus of $0.10; revenues rose 17.4% year/year to $65.3 mln vs the $57.7 mln consensus. Co issues in-line guidance for Q2, sees EPS of $0.10-0.14, excluding non-recurring items, vs. $0.11 consensus. Co issues in-line guidance for FY10, sees EPS of $0.40-0.48, excluding non-recurring items, vs. $0.47 consensus. On February 2, 2010, the co's Board of Directors approved an additional $10.0 million for the share repurchase program. The Company had $1.0 million remaining in the share repurchase program from the original authorization on December 2, 2008, resulting in $11.0 million currently available. "We expect GMV for fiscal year 2010 to range from $360 million to $400 million. We expect GMV for Q2-10 to range from $85 million to $95 million." | ||
| 16:07 | IN Intermec beats by $0.07, beats on revs; guides Q1 EPS in-line, revs in-line (12.95 -0.72) | |
| Reports Q4 (Dec) earnings of $0.12 per share,ex-items, $0.07 better than the First Call consensus of $0.05; revenues fell 19.1% year/year to $179.1 mln vs the $166.5 mln consensus. Co issues in-line guidance for Q1, sees EPS of $0.01-$0.05, ex-items, vs. $0.03 consensus; sees Q1 revs of $155-$165 mln vs. $161.65 mln consensus. | ||
| 16:07 | BRKR Bruker Corp. see Q4 revs greater than $355 mln, up from $340mln+ prior guidance, vs $327.49 mln First Call consensus (12.27 -0.44) | |
| 16:07 | VRTX Vertex Pharm reports EPS in-line, beats on revs (38.42 -1.81) | |
| Reports Q4 (Dec) loss of $0.85 per share, in-line with the First Call consensus of ($0.85); revenues rose 43.7% year/year to $34.1 mln vs the $27.9 mln consensus. "Vertex enters 2010 in a strong financial position to support the continued advancement of our business throughout what we believe will be a defining year for our company... Our increased investment in launch preparation activities for telaprevir is aimed at ensuring a rapid and successful potential launch. Further, to support our goal of becoming a fully-capable biopharmaceutical company, Vertex continues to invest in other product opportunities across our business, including multiple proof-of-concept clinical trials and compounds emerging from research... Our primary focus remains on the completion of the telaprevir Phase 3 development program and the subsequent submission of a New Drug Application for telaprevir, planned for the second half of 2010. In addition, we plan to initiate a clinical trial evaluating combination regimens of telaprevir and VX-222 aimed at further driving the evolution of HCV care, and we look forward to obtaining interim clinical data from the trial in the third quarter of 2010... In cystic fibrosis, the Phase 3 program for VX-770, our lead CFTR potentiator, is advancing rapidly, and based on data generated in this program, we plan to submit an NDA for VX-770 in the second half of 2011. Additionally, we recently announced results from a preliminary analysis of data from a Phase 2a trial of VX-809, our lead CFTR corrector. Based on these data, we plan to initiate a clinical trial of VX-809 dosed in combination with VX-770 in patients with the most common mutation of CF, known as F508del, in the second half of 2010." | ||
| 16:07 | FALC FalconStor Sftwr misses by $0.05, misses on revs (3.07 -0.32) | |
| Reports Q4 (Dec) loss of $0.02 per share, excluding non-recurring items, $0.05 worse than the First Call consensus of $0.03; revenues fell 4.1% year/year to $22.4 mln vs the $25.1 mln consensus. | ||
| 16:05 | ATGN AltiGen Comms announced that Bank of Beijing has deployed an AltiGen software-based call center and Voice-over-IP solution as part of its customer service solution (0.81 -0.03) | |
| 16:05 | MCRS Micros Systems beats by $0.02, reports revs in-line (27.40 -1.68) | |
| Reports Q2 (Dec) earnings of $0.36 per share, excluding non-recurring items, $0.02 better than the First Call consensus of $0.34; revenues fell 4.6% year/year to $225.6 mln vs the $225.1 mln consensus. Co said, "The financial statements reported today reflect adjustments necessitated by certain fraudulent activities recently uncovered in our Japanese subsidiary and perpetrated by one employee who is not a member of senior management. The co immediately initiated an investigation, which is now substantially complete, and determined that the cumulative income statement effect over the last five fiscal years of this activity is an overstatement of revenue of ~$6.9 mln and pre-tax income of ~$4.4 mln. The co does not believe that adjustments to correct information in any prior reporting period would be material. The condensed consolidated statements of operations and cash flows reported today do not reflect cumulative adjustments, but include adjustments for the periods presented." | ||
| 16:05 | OPWV Openwave beats by $0.03, beats on revs (2.15 -0.10) | |
| Reports Q2 (Dec) earnings of $0.04 per share, $0.03 better than the First Call consensus of $0.01; revenues rose 3.3% year/year to $49.7 mln vs the $46.8 mln consensus. | ||
| 16:04 | BMRN Biomarin Pharm to acquire LEAD Therapeutics (20.34 -0.80) -Update- | |
| Co announced that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers. Under the terms of the stock purchase agreement, BioMarin will pay to the stockholders of LEAD $18 million upfront and will pay an additional $11 million upon acceptance of the IND filing (filing expected by the end of 2010), and up to $68 million for development and launch milestones for LT-673. As a result of this acquisition, BioMarin expects to incur approximately $11.0 to $13.0 million in operating expenses and acquisition related charges in 2010. Subject to customary closing conditions, the acquisition is expected to be completed by mid-February 2010. | ||
| 16:04 | BEBE bebe stores beats by $0.02, misses on revs; guides Q3 EPS in-line (6.28 -0.24) | |
| Reports Q2 (Dec) earnings of $0.03 per share, $0.02 better than the First Call consensus of $0.01; revenues fell 22.2% year/year to $141.5 mln vs the $144.5 mln consensus. Co issues in-line guidance for Q3, sees EPS of ($0.05)-0.00 vs. ($0.03) consensus, with a comparable store sales decrease less negative than the previous quarter comparable store sales (22.5%). Gross margin as a percentage of net sales increased to 39.2% in the second quarter of fiscal 2010, compared to 38.6% in the second quarter of fiscal 2009. The increase in gross margin as a percentage of net sales from the prior year of 0.6% was primarily due to lower markdowns and lower other costs including inventory shrink and damages partially offset by lower initial markup and unfavorable occupancy leverage. | ||
| 16:04 | SNCR Synchronoss Tech beats by $0.02, beats on revs (16.49 -0.75) | |
| Reports Q4 (Dec) earnings of $0.20 per share, $0.02 better than the First Call consensus of $0.18; revenues rose 14.0% year/year to $35.6 mln vs the $34.4 mln consensus. | ||
| 16:04 | EGOV NIC Inc misses by $0.02, reports revs in-line; guides FY10 revs below consensus (8.24 -0.26) | |
| Reports Q4 (Dec) earnings of $0.04 per share, $0.02 worse than the First Call consensus of $0.06; revenues rose 43.9% year/year to $36.4 mln vs the $36.7 mln consensus. Co issues downside guidance for FY10, sees FY10 revs of $156-$161 mln vs. $166.69 mln consensus. The company also currently expects operating income to range from $24.0 - $26.5 million and net income of $14.5 - $16.0 million. Co states, "While our financial guidance has been tempered somewhat by the current state budget crisis and macroeconomic-related weakness, we currently expect continued steady organic growth in 2010, with total same-state portal revenues expected to grow approximately 10 percent, in line with the 10 to 15 percent growth we've experienced historically." | ||
| 16:04 | PTEC Phoenix Tech beats by $0.19, misses on revs (3.15 -0.11) | |
| Reports Q1 (Dec) earnings of $0.11 per share, excluding non-recurring items, $0.19 better than the First Call consensus of ($0.08); revenues fell 12.8% year/year to $15.6 mln vs the $17.3 mln consensus. | ||
| 16:03 | MTD Mettler-Toledo beats by $0.12, beats on revs; guides Q1 EPS below consensus; guides FY10 EPS in-line (96.29 -3.95) | |
| Reports Q4 (Dec) earnings of $2.09 per share, $0.12 better than the First Call consensus of $1.97; revenues rose 0.4% year/year to $511.7 mln vs the $505.4 mln consensus. Co issues downside guidance for Q1, sees EPS of $0.98-1.04 vs. $1.06 consensus. Co issues in-line guidance for FY10, sees EPS of $5.90-6.15 vs. $6.13 consensus. Based on today's assessment, management anticipates that local currency sales growth in 2010 will be in the range of 3% to 5%. | ||
| 16:03 | LMNX Luminex beats by $0.06, beats on revs; guides FY10 revs in-line (13.78 -0.32) | |
| Reports Q4 (Dec) earnings of $0.13 per share, $0.06 better than the First Call consensus of $0.07; revenues rose 35.5% year/year to $38.2 mln vs the $35.8 mln consensus. Co issues in-line guidance for FY10, sees FY10 revs of $138-148 mln vs. $141.32 mln consensus. | ||
| 16:03 | PBI Pitney Bowes beats by $0.03, reports revs in-line; reaffirms FY10 EPS guidance, revs guidance (21.31 ) | |
| Reports Q4 (Dec) earnings of $0.64 per share, excluding non-recurring items, $0.03 better than the First Call consensus of $0.61; revenues fell 6.4% year/year to $1.45 bln vs the $1.46 bln consensus. Co reaffirms guidance for FY10, sees EPS of $2.30-2.50 vs. $2.42 consensus; sees FY10 revs up 0-3% (roughly $5.57-5.74 bln) vs. $5.63 bln consensus. | ||
| 16:03 | TWLL Techwell beats by $0.02, beats on revs; guides Q1 revs in-line (10.79 -0.77) | |
| Reports Q4 (Dec) earnings of $0.22 per share, excluding non-recurring items, $0.02 better than the First Call consensus of $0.20; revenues rose 38.2% year/year to $22.8 mln vs the $22 mln consensus. Co issues in-line guidance for Q1, sees Q1 revs of $19.5-20.5 mln vs. $20.07 mln consensus. | ||
| 16:02 | COGO Cogo Group beats by $0.01, beats on revs; guides Q1 EPS in-line, revs in-line (6.56 -010) | |
| Reports Q4 (Dec) earnings of $0.19 per share, $0.01 better than the First Call consensus of $0.18; revenues rose 7.0% year/year to $88.1 mln vs the $86.9 mln consensus. Co issues in-line guidance for Q1, sees EPS of $0.14-0.15 vs. $0.14 consensus; sees Q1 revs of $70.72 mln vs. $70.04 mln consensus. | ||
| 16:02 | USAK USA Truck says there is no direct or indirect relationship between co and USA Dry Van Logistics (12.20 ) | |
| Co announced that it has been made aware of a Chapter 11 bankruptcy filing that has been made by USA Dry Van Logistics, LLC and USA Carriers, affiliated companies based in McAllen, Texas. USA Truck, Inc. wishes to inform the public that there is no direct or indirect relationship between such companies and USA Truck, Inc. | ||
| 16:02 | OPXT Opnext misses by $0.01, misses on revs; guides Q4 revs in-line (1.90 -0.04) | |
| Reports Q3 (Dec) loss of $0.14 per share, excluding non-recurring items, $0.01 worse than the First Call consensus of ($0.13); revenues rose 7.8% year/year to $76.1 mln vs the $78.3 mln consensus. Co issues in-line guidance for Q4, sees Q4 revs of $78-83 mln vs. $81.5 mln consensus. | ||
| 16:01 | HA Hawaiian Airlines, Inc. beats by $0.07, beats on revs (6.08 -0.19) | |
| Reports Q4 (Dec) earnings of $0.19 per share, excluding non-recurring items, $0.07 better than the First Call consensus of $0.12; revenues fell 1.2% year/year to $297 mln vs the $284.8 mln consensus. | ||
| 16:01 | ALKS Alkermes beats by $0.09, beats on revs (10.52 -0.57) | |
| Reports Q3 (Dec) loss of $0.07 per share, $0.09 better than the First Call consensus of ($0.16); revenues fell 71.6% year/year to $44.2 mln vs the $39.7 mln consensus. "The record RISPERDAL CONSTA sales in our third quarter underscore the increasing importance of this medication in the marketplace," commented James Frates, Chief Financial Officer of Alkermes. "VIVITROL also had a strong quarter with double-digit growth. We will continue to focus on financial performance while leveraging our financial strength to invest in Alkermes' proprietary pipeline and research and development efforts." | ||
| 16:01 | ALKS Alkermes beats by $0.09, beats on revs (10.52 -0.57) | |
| Reports Q3 (Dec) loss of $0.07 per share, $0.09 better than the First Call consensus of ($0.16); revenues fell 71.6% year/year to $44.2 mln vs the $39.7 mln consensus. At December 31, 2009, Alkermes had cash and total investments of $357.5 million, compared to $369.5 million at September 30, 2009. | ||
| 16:01 | EGOV NIC Inc: The state of Nebraska has signed a new contract with Nebraska Interactive (8.24 -0.26) | |
| The state of Nebraska has signed a new contract with Nebraska Interactive, part of eGovernment firm NIC's family of companies, to manage its official government portal for up to 6 years. The contract has an initial term of four years with one, two-year renewal option. | ||
| 16:00 | FIS Fidelity National Information Services announces three-year stock repurchase program; of up to 15 mln shares (23.59 -0.40) | |
| Co announced that its Board of Directors has approved a three-year stock repurchase program under which the co may repurchase up to 15 mln shares of its common stock. Purchases may be made from time to time by the co in the open market at prevailing market prices or in privately negotiated transactions through January 31, 2013. | ||
| 16:00 | BMRN BioMarin Reports "Encouraging" Preliminary Data on BMN 110 for MPS IVA; co to host conf call at 5 p.m. ET (20.39 -0.75) | |
| Co announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. "Although still early, we are encouraged by these initial signals of efficacy of GALNS enzyme replacement therapy for Morquio disease. Additional results will become available following the 2.0 mg/kg dose phase, but compared to other studies we have conducted in MPS diseases, we feel encouraged by the reduction in KS and improvements in walk distance and stair climb. Based on these results, we feel more confident about endurance as a primary endpoint for a Phase III trial and that a Phase III trial can be conducted as expeditiously as previous trials of enzyme replacement therapy," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin." Key Observations: Keratan sulfate (KS) levels fall within a few weeks after the start of therapy; Improvements in 6-minute walk distance and 3-minute stair climb at 24 weeks are consistent with those observed with clinical studies for MPS I, MPS II, and MPS VI; frequency and severity of infusion reactions appear comparable to those observed with Naglazyme and Aldurazyme. | ||
| 16:00 | QGEN Qiagen unit and Pfizer enter into an agreement to develop a companion diagnostic for brain tumor patients (21.17 -0.69) | |
| Pfizer (PFE) and DxS (a wholly owned subsidiary of QIAGEN) today announce that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of the diagnostic agreement have not been disclosed. On April 16, 2008, Pfizer and Celldex Therapeutics (CLDX) entered into an agreement to grant Pfizer an exclusive worldwide license to PF-04948568 (CDX-110) which is currently in Phase 2 clinical development for the treatment of newly diagnosed GBM. | ||
Feeds!